Date: 2017-10-06
Type of information: Nomination
Compound: VP business and corporate development
Company: Amicus Therapeutics (USA - NJ)
Therapeutic area: Rare diseases - Genetic diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On October 6, 2017, Amicus Therapeutics announced the appointment of Michael C. Diem, MD as Senior Vice President of Business and Corporate Development. He will be responsible for leading all business and corporate development activities. Dr. Diem will be a key member of the Amicus senior leadership team reporting to John F. Crowley, Chairman and Chief Executive Officer of Amicus.
- Dr. Diem is a driven business executive and physician with 12 years of global experience in the pharmaceutical and biotechnology industries, including leadership roles in corporate and business development at AstraZeneca and GSK Rare Diseases. He also has more than nine years of experience in academic and clinical medicine. Prior to joining Amicus, Dr. Diem was Senior Vice President of Corporate and Business Development at Aevi Genomic Medicine, where he led all business development and licensing activities. Previously, Dr. Diem was the Global Head of Corporate Strategy and Corporate Development for AstraZeneca, where he was responsible for mergers and acquisitions, externalization opportunities and divestitures, global opportunities in new areas of business and the company's strategic investment activities (including MedImmune Ventures). Prior to joining AstraZeneca, Dr. Diem was the Head of Business Development for GSK Rare Diseases where he led the partnerships, licensing and mergers and acquisitions activities that formed the Company's rare disease portfolio. Earlier he was a partner in GSK's corporate venture capital firm, SR One, Limited and served on the boards of numerous companies. Prior to GSK, Mike was an associate at Frantz Medical Ventures and practiced medicine for six years.
- Dr. Diem holds a BA in biological sciences from Rutgers University, an MD from the Rutgers-Robert Wood Johnson Medical School and an MBA from the Weatherhead School of Management at Case Western Reserve University. He completed his medical training at Duke University Medical Center and is an alumnus of the Kauffman Fellows Program. Mike is currently a board director at VenatoRx Pharmaceuticals and is a member of the board of governors of the Boys and Girls Clubs of Philadelphia.
Financial terms:
Latest news:
Is general: Yes
